在患有血液性恶性瘤的患者中,在CAR T细胞治疗后出现的第二种原发性恶性瘤
Elvira Umyarova1, Charles Pei2, William Pellegrino2
1Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. Elvira.Umyarova@osumc.edu.
Journal of hematology & oncology
|March 18, 2025
概括
化学抗原受体T细胞 (CAR-T) 治疗可以导致血液癌症患者的第二次原发性恶性瘤 (SPMs). 警监测对于CAR-T幸存者至关重要,因为潜在的长期风险.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 癌症研究 癌症研究
背景情况:
- 化学抗原受体T细胞 (CAR-T) 疗法已经彻底改变了复发性/耐药性血液恶性瘤的治疗方法.
- 关于CAR-T治疗后的长期并发症的数据有限.
- 这项研究追溯分析了246名接受CAR-T治疗B细胞淋巴瘤和多发性骨髓瘤的患者.
研究的目的:
- 研究在接受CAR-T治疗的患者中SPM的发生率和模式.
- 评估长期结果并确定与CAR-T相关的潜在风险.
- 为了为CAR-T幸存者的未来监控策略提供信息.
主要方法:
- 对246名用CAR-T治疗的R/R B细胞淋巴瘤或多发性骨髓瘤患者的回顾性分析.
- 最少两年的随访期.
- 收集了关于患者人口统计,先前治疗和SPM发展的数据.
主要成果:
- 21名患者 (8.5%) 患有SPM,平均随访时间为38个月.
- 非黑色素瘤皮肤癌是最常见的SPM (52%),其次是血液恶性瘤 (33%) 和非皮肤固体瘤 (14%).
- 发现了状细胞癌,骨髓质疏松综合征,急性骨髓性白血病和各种固体瘤.
结论:
- 观察到的SPM模式表明了潜在的CAR-T相关风险.
- 对CAR-T幸存者进行警的治疗后监测是有必要的.
- 需要进一步的研究来阐明SPM风险的机制和预测因素.
相关概念视频
01:27Tumor Immunotherapy
454
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
454
01:21Stem Cell Therapy for Tissue Regeneration
4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
02:40Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
02:30Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K